600196 复星医药
2025/06 - 中期
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入19,514,432-4.63%41,067,19641,399,54043,951,54739,011,184
减:营业总成本18,904,363-2.60%39,397,51241,284,07741,346,26437,093,266
    其中:营业成本10,123,465-3.25%21,365,57421,595,30923,169,69020,229,785
               财务费用640,3158.74%1,110,518984,323647,403464,022
               资产减值损失(64,270)218.59%(96,570)(219,742)(272,488)(829,873)
公允价值变动收益(48,597)-82.79%(115,939)(427,380)(2,498,368)352,299
投资收益2,120,17799.68%2,104,6073,501,9934,377,8434,623,826
    其中:对联营企业和合营企业的投资收益929,66110.50%1,643,8392,184,8491,835,1461,789,137
营业利润2,761,20843.12%4,245,1043,307,5084,656,6566,302,568
利润总额2,718,48240.77%4,169,2823,264,5684,574,3826,042,671
减:所得税费用618,27162.08%656,841369,504626,9171,066,401
净利润2,100,21135.52%3,512,4402,895,0633,947,4644,976,269
减:非控股权益398,24322.56%742,554508,798216,660247,559
股东净利润1,701,96838.96%2,769,8872,386,2663,730,8054,728,711

市场价值指针
每股收益 (元) *0.64039.13%1.0400.8901.4301.850
每股派息 (元) *----0.3200.2700.4200.560
每股净资产 (元) *17.7490.99%17.70017.11016.68415.292
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容